Ananda Pharma PLC has announced plans to withdraw its shares from the AQSE Growth Market and re-register as a private company, proposing to continue operations under the name Ananda Pharma
Ananda Pharma to delist from AQSE and go private to refocus on drug development
Ananda Pharma PLC has announced plans to withdraw from the AQSE Growth Market and re-register as a private company, citing the high cost of being publicly listed, regulatory complexity and
Ananda Pharma plc (AQSE: ANA, OTC: ANANF) Webinar Presentation Release
Ananda Pharma plc (AQSE: ANA, OTC: ANANF), a UK-based biopharmaceutical company developing regulatory approved, cannabidiol medicines to treat complex, chronic conditions, is pleased to announce that the post annual report corporate
Ananda Pharma plc (AQSE: ANA) Appointment of Commercial Adviser
Ananda Pharma plc (AQSE: ANA), a UK company focused on the development of cannabinoid therapies targeting the treatment of complex, chronic inflammatory pain conditions is pleased to announce the appointment of Andy Rust as
An Introduction to Ananda Developments
Finance Director Jeremy Sturgess-Smith introduces Ananda Developments, outlining the company’s mission, strategic focus, and what makes it distinct within the CBD and drug development sectors.
Ananda (AQSE:ANA) Developments Secures Funding for Endometriosis Clinical Trial
Ananda Developments Plc (AQSE: ANA), a developer of cannabinoid medicines, has secured the necessary funding to initiate a trial to test the effectiveness of its cannabidiol oil, MRX1, in treating
Ananda Developments (AQSE:ANA) First Cannabinoid Medicines Launched
Ananda’s ambition is to be a leading provider of high-quality cannabinoid-based medicines for the treatment of complex, chronic inflammatory pain conditions.
Company Profile (AQSE:ANA) Ananda Developments
Ananda Developments (AQSE: ANA) is an AQUIS-listed healthcare company involved in the development of cannabinoid-based medicines with two concurrently running, third-party funded, Phase II randomised control trials (RCTs).
Zak Mir talks to Melissa Sturgess, CEO Ananda Developments
In the wake of the MRX Global acquisition, and what this means for the medical cannabis group
Ananda Developments Plc (ANA.L) Grant of Home Office Licence
The Directors of Ananda announce the following progress regarding Ananda’s vision to become a significant participant in the emerging medicinal cannabis sector: